RudaCure attended Bio-欧洲 Spring held in 意大利米兰 from March 10th to explore 兽药 partners and conduct a meeting with Ceva, the French partner company currently conducting PoC research on RCI001-AH.
At Bio-欧洲, a meeting with Boehringer Ingelheim included discussions about RCI002-AH, with both parties agreeing to proceed with follow-up activities.
Simultaneously, the team visited Ceva to discuss interim results of the ongoing RCI001-AH PoC and plan future schedules.
While we cannot disclose detailed information due to contractual obligations, RudaCure is committed to maximizing the value of each 管线 developed through its proprietary technology.